At Poolbeg Pharma we are developing a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS), POLB 001. POLB 001 is a phase 2-ready oral p38 MAPK inhibitor for the prevention of CRS experienced by >70% of patients on certain bispecific antibodies & CAR T therapies. With currently no approved therapies for the prevention of this potentially life-threatening condition, POLB 001 has the potential to remedy a significant unmet clinical need. Learn more about POLB 001in oncology: https://lnkd.in/eGgQBKFA #POLB #Oncology #Cancer #CRS #MedicalNeed #ScientificResearch #Phase2 #Immunotherapies
Poolbeg Pharma plc
Biotechnology Research
Focused on the development & commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
40 Bank Street, Floor 24
London, E14 5NR, GB
-
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Dublin, London & Vienna, Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at Euro Green…
Updates
-
Our CEO Jeremy Skillington, PhD speaks with Martin Luke from Vox Markets at the Business Design Centre during the Master Investor Show on Saturday. 🤝 Attending Master Investor 🎤 #BIOTrinity conference ✅ Partnering Oral GLP1 & POLB 001 🔑 Key message to investors Learn more: https://lnkd.in/eGtUUVUm #POLB #MasterInvestor #BusinessDesignCentre #London #AIM #Pharma
-
A reminder that Our Chief Executive Officer Jeremy Skillington, PhD will be presenting our exciting POLB 001 data & Oral GLP1 agonist today at OBN (UK) Ltd's BioTrinity conference in London. 👉 Session: Science Spotlight 8 - Rare Disease Meet Jeremy there to learn more about our programmes. Learn more: https://lnkd.in/eHZCGhZM #POLB #BioTrinity #London #AIM #Conference
-
-
The team had a great time at Master Investor at the Business Design Centre on Saturday. Our CEO, Jeremy Skillington, PhD, took the stage to share insights on our exciting pipeline of high value programmes and future plans. The team had the opportunity to engage with both new and existing investors at our booth, showcasing the exciting developments and exciting times ahead for Poolbeg Pharma. A big thank you to everyone who stopped by our booth! #POLB #Conference #InvestorConference #MasterInvestor #London #BusinessDesignCentre #InvestorRelations
-
-
-
-
-
+1
-
-
A reminder that our CEO Jeremy Skillington, PhD will be presenting at Master Investor on the Showcase Stage, located on the ground floor. 📅 Saturday 29 March 2025 🕐 1pm 📍 Business Design Centre Ltd, 52 Upper St, London N1 0QH You can meet our industry leading team at Booth M30 to learn more about Poolbeg Pharma's high value programmes targeting diseases with a high unmet medical need. Reminder to get your free ticket here: https://lnkd.in/ezGVkCDE #POLB #MasterInvestor25 #Investor #AIM
-
-
We will be participating in three key Conferences in March and April 2025: ✅ Master Investor Show - Saturday 29 March ✅ OBN (UK) Ltd's BioTrinity - Wednesday 2 April ✅ LSX World Congress - Wednesday 30 April Meet us there to learn more about the development of Poolbeg's innovative medicines to address unmet medical needs. Learn more: https://lnkd.in/eBv58pe2 #POLB #Conferences #MasterInvestor25 #BioTrinity #LSXConference
-
Highlight from our recent Investor Meet Company presentation! Poolbeg Pharma is developing an Oral Encapsulated GLP-1 agonist. 👉 US$347.5 billion economic impact of obesity on US businesses & employees 📈 Significant market projection ➡️ 42% of US population impacted by obesity Poolbeg's delivery system encapsulates peptides for oral delivery to specific areas of the gut, using pH sensitive release mechanism, and into systemic circulation with the aim of enhancing bioavailability & improving convenience. #POLB #GLP1 #Obesity #MetabolicDisease
-
Poolbeg Pharma's NED and Scientific Advisory Board member, Professor Luke O'Neill sheds light on POLB 001's in the oncology space. POLB 001 has the potential to be an effective oral preventative therapy to address the significant unmet medical need in cancer immunotherapy-induced Cytokine Release Syndrome (CRS). #Cancer #CRS #CART #ScientificResearch #POLB #Oncology
-
The Korean Intellectual Property Office has notified its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to December 2038. 👉 Claims cover POLB 001 for the treatment of severe influenza ✅ POLB 001 has strong potential across multiple disease areas 🤝 Further strengthening our global IP portfolio & enhancing the value & attractiveness of POLB 001 for prospective partners Learn more: https://lnkd.in/eRSw_fYj #POLB #Patent #IntellectualProperty #PatentProtection
-
Our Chief Executive Officer Jeremy Skillington, PhD will be presenting Poolbeg Pharma, our exciting drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS at OBN (UK) Ltd's Bio Trinity in London. 📅 Wednesday 2 April 👉 Session: Science Spotlight 8 - Rare Disease Meet Jeremy there to learn more about our high value programmes. Learn more: https://lnkd.in/eHZCGhZM #POLB #BioTrinity #London
-